These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 2323678)

  • 1. Fibrinogen Barcelona II: a new case of A alpha 16 Arg----His substitution.
    Borrell M; Vila L; Solá J; Coll I; Fontcuberta J
    Haemostasis; 1990; 20(1):1-7. PubMed ID: 2323678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrinogen Milano. VI: A heterozygous dysfibrinogenemia (A alpha 16 Arg----His) with bleeding tendency.
    Bögli C; Cofrancesco E; Cortellaro M; Della Volpe A; Hofer A; Furlan M; Zanussi C
    Eur J Haematol; 1990 Jul; 45(1):26-30. PubMed ID: 2379562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed release of an abnormal fibrinopeptide A from fibrinogen Manchester: effect of the A alpha 16 Arg leads to His substitution upon fibrin monomer polymerization and the immunological crossreactivity of the peptide.
    Lane DA; Southan C; Ireland H; Thompson E; Kehl M; Henschen A
    Br J Haematol; 1983 Apr; 53(4):587-97. PubMed ID: 6830702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinogen Kiel: a congenital dysfibrinogenaemia with (A alpha-16 Arg----His) substitution characterized by HPLC without prior isolation of fibrinogen.
    Seydewitz HH; Gram J; Bruhn HD; Witt I
    Blood Coagul Fibrinolysis; 1991 Aug; 2(4):501-6. PubMed ID: 1768762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrinogen kaiserslautern III: a new case of congenital dysfibrinogenemia with aalpha 16 arg-->cys substitution.
    Loreth RM; Meyer M; Albert FW
    Haemostasis; 2001; 31(1):12-7. PubMed ID: 11408744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinogen Seattle II: congenital dysfibrinogenemia with an Arg (A alpha 16)----his substitution.
    Ebert RF; Schreiler WE; Bell WR
    Thromb Res; 1986 Jul; 43(1):7-13. PubMed ID: 3726812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinogen Kawaguchi: an abnormal fibrinogen characterized by defective release of fibrinopeptide A.
    Matsuda M; Saeki E; Kasamatsu A; Nakamikawa C; Manabe S; Samejima Y
    Thromb Res; 1985 Feb; 37(3):379-90. PubMed ID: 3992527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinogen Milano IV, another case of congenital dysfibrinogenemia with an abnormal fibrinopeptide A release (A alpha 16 Arg----His).
    Bögli C; Hofer A; Baudo F; Redaelli R; Furlan M
    Haemostasis; 1992; 22(1):7-11. PubMed ID: 1521828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrinogen Sapporo: dysfibrinogenemia characterized by the replacement of A alpha arginine-16 by histidine resulting in the delayed release of fibrinopeptide A by thrombin.
    Asakura S; Terukina S; Yamazumi K; Matsuda M; Murayama H; Higuchi A; Musashi M; Sakurada K; Miyazaki T
    Nihon Ketsueki Gakkai Zasshi; 1989 Sep; 52(6):1094-104. PubMed ID: 2588959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrinogen Ledyard (A alpha Arg16----Cys): biochemical and physiologic characterization.
    Lee MH; Kaczmarek E; Chin DT; Oda A; McIntosh S; Bauer KA; Clyne LP; McDonagh J
    Blood; 1991 Oct; 78(7):1744-52. PubMed ID: 1912564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinogen Geneva, a new case of A alpha 16 Arg----Cys dysfibrinogenaemia.
    Furlan M; Bögli C; Hofer A; Bouvier CA; de Moerloose P
    Blood Coagul Fibrinolysis; 1990 Jun; 1(2):139-43. PubMed ID: 2130925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinogen Manchester: identification of an abnormal fibrinopeptide A with a C-terminal arginine leads to histidine substitution.
    Southan C; Kehl M; Henschen A; Lane DA
    Br J Haematol; 1983 May; 54(1):143-51. PubMed ID: 6849832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinogen Birmingham: a heterozygous dysfibrinogenemia (A alpha 16 Arg----His) containing heterodimeric molecules.
    Siebenlist KR; Prchal JT; Mosesson MW
    Blood; 1988 Mar; 71(3):613-8. PubMed ID: 3345340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new congenital abnormal fibrinogen Ise characterized by the replacement of B beta glycine-15 by cysteine.
    Yoshida N; Wada H; Morita K; Hirata H; Matsuda M; Yamazumi K; Asakura S; Shirakawa S
    Blood; 1991 May; 77(9):1958-63. PubMed ID: 2018836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombin-induced fibrinopeptide release from a fibrinogen variant (fibrinogen Sydney I) with an Aalpha Arg-16----His substitution.
    Southan C; Lane DA; Bode W; Henschen A
    Eur J Biochem; 1985 Mar; 147(3):593-600. PubMed ID: 3979390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fibrinogen Bern III: a further case of hereditary fibrinogen variants with substitution A alpha 16 Arg----Cys].
    Furlan M; Leupin L; Biasiutti FD; Lämmle B
    Schweiz Med Wochenschr; 1991 Jul; 121(29):1068-71. PubMed ID: 1891701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinogens Bern IV, Bern V and Milano XI: three dysfunctional variants with amino acid substitutions in the thrombin cleavage site of the Aalpha-chain.
    Stucki B; Zenhäusern R; Biedermann B; Baudo F; Redaelli R; Lämmle B; Furlan M
    Blood Coagul Fibrinolysis; 1999 Mar; 10(2):93-9. PubMed ID: 10192658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel structure elucidation strategy for genetically abnormal fibrinogens with incomplete fibrinopeptide release as applied to fibrinogen Schwarzach.
    Henschen A; Kehl M; Deutsch E
    Hoppe Seylers Z Physiol Chem; 1983 Dec; 364(12):1747-51. PubMed ID: 6667926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fibrinogen Bern II: hereditary fibrinogen variant with amino acid substitution of arginine replaced by histidine in position 16 of the A alpha chain].
    Rupp C; Sievi R; Furlan M; Beck EA
    Schweiz Med Wochenschr; 1983 Oct; 113(40):1460-2. PubMed ID: 6648427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrinopeptide A release is necessary for effective B:b interactions in polymerisation of variant fibrinogens with impaired A:a interactions.
    Soya K; Terasawa F; Okumura N
    Thromb Haemost; 2013 Feb; 109(2):221-8. PubMed ID: 23238100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.